Theralink Technologies Inc (THER)

[tr1205]

PPS likely .05 or greater? 10Q indicates per share price return around .05 , at least this is what I got from reading the materials.

Looking at the FDA process charts the fastest we could get through phase 2 is several months to 2 years . Likely still a few years away from market if that is the only formula OncBioMune follows, however, there are some wild cards to getting to market sooner that are other possibilities, as I see them:

1. Right to try legislation, may allow early adoption.

2. Getting an FDA Breakthrough Therapy Designation for the vaccine. (Approval of drugs that provide a substantial improvement over what is currently available to treat a serious disease or condition)

3. FDA expedited Access pathway. The Expedited Access Pathway (EAP) program is a voluntary program for certain medical devices that demonstrate the potential to address unmet medical needs for life threatening or irreversibly debilitating diseases or conditions that are subject to premarket approval applications (PMA), premarket notification (510[k]) or requests for De Novo designation.
( this has been mentioned by the company, that it is pursuing)